CN103655563A - 抑制突变型c-kit的方法 - Google Patents

抑制突变型c-kit的方法 Download PDF

Info

Publication number
CN103655563A
CN103655563A CN201210378267.5A CN201210378267A CN103655563A CN 103655563 A CN103655563 A CN 103655563A CN 201210378267 A CN201210378267 A CN 201210378267A CN 103655563 A CN103655563 A CN 103655563A
Authority
CN
China
Prior art keywords
kit
patient
compound
proliferative disease
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201210378267.5A
Other languages
English (en)
Chinese (zh)
Inventor
V·K·柴恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arog Pharmaceuticals LLC
Original Assignee
Arog Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arog Pharmaceuticals LLC filed Critical Arog Pharmaceuticals LLC
Priority to CN201810781649.XA priority Critical patent/CN109010340A/zh
Publication of CN103655563A publication Critical patent/CN103655563A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201210378267.5A 2012-09-26 2012-09-29 抑制突变型c-kit的方法 Pending CN103655563A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810781649.XA CN109010340A (zh) 2012-09-26 2012-09-29 抑制突变型c-kit的方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261705838P 2012-09-26 2012-09-26
US61/705,838 2012-09-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810781649.XA Division CN109010340A (zh) 2012-09-26 2012-09-29 抑制突变型c-kit的方法

Publications (1)

Publication Number Publication Date
CN103655563A true CN103655563A (zh) 2014-03-26

Family

ID=50295125

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201210378267.5A Pending CN103655563A (zh) 2012-09-26 2012-09-29 抑制突变型c-kit的方法
CN201810781649.XA Pending CN109010340A (zh) 2012-09-26 2012-09-29 抑制突变型c-kit的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810781649.XA Pending CN109010340A (zh) 2012-09-26 2012-09-29 抑制突变型c-kit的方法

Country Status (8)

Country Link
US (3) US9480683B2 (enExample)
JP (1) JP6042157B2 (enExample)
KR (2) KR20140040594A (enExample)
CN (2) CN103655563A (enExample)
AU (1) AU2013204841B2 (enExample)
CA (1) CA2812258C (enExample)
MX (1) MX368707B (enExample)
TW (1) TWI599356B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107382983A (zh) * 2017-08-24 2017-11-24 扬州市三药制药有限公司 一种治疗白血病药物的合成方法
WO2018014519A1 (zh) * 2016-07-18 2018-01-25 北京雅康博生物科技有限公司 用于检测c-kit基因突变的引物、探针及试剂盒

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101738063B1 (ko) 2012-09-21 2017-05-19 아로그 파마슈티칼스, 인코퍼레이티드 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型ｃ－ｋｉｔ的方法
US10835525B2 (en) 2012-09-26 2020-11-17 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
US11642340B2 (en) 2012-09-26 2023-05-09 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
PT3468966T (pt) 2016-06-10 2020-11-10 Vitae Pharmaceuticals Llc Inibidores da interação menina-mll
CN108778276A (zh) 2016-11-02 2018-11-09 安罗格制药有限责任公司 用于治疗flt3突变型增殖性疾患相关突变的克莱拉尼
DE102019204219A1 (de) * 2019-03-27 2020-10-01 Robert Bosch Gmbh Verfahren zur Diagnose von Abgassensoren
US11471451B2 (en) * 2019-08-19 2022-10-18 Arog Pharmaceuticals, Inc. Uses of crenolanib
WO2021238957A1 (zh) * 2020-05-26 2021-12-02 江苏恒瑞医药股份有限公司 法米替尼在制备用于治疗c-KIT或PDGFRA突变的肿瘤的药物中的用途
CA3186319A1 (en) * 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US11713310B2 (en) 2020-07-20 2023-08-01 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
WO2022090547A1 (en) 2020-10-30 2022-05-05 Dsm Ip Assets B.V. Production of carotenoids by fermentation
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
JP2024506758A (ja) * 2021-02-09 2024-02-14 ジャスパー・セラピューティクス・インコーポレイテッド 改変された幹細胞組成物およびその使用方法
CN113683594B (zh) * 2021-09-07 2022-12-27 曲靖师范学院 一种喹啉-苯并咪唑盐类化合物及其合成方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678604A (zh) * 2002-08-28 2005-10-05 辉瑞产品公司 可用作抗增殖剂的新苯并咪唑衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
KR20070092333A (ko) 2003-06-24 2007-09-12 화이자 프로덕츠 인크. 1-[(벤조이미다졸-1-일)퀴놀린-8-일]피페리딘-4-일아민유도체의 제조 방법
US20130230511A1 (en) * 2012-02-03 2013-09-05 Board Of Regents, The University Of Texas System Biomarkers for response to tyrosine kinase pathway inhibitors in cancer
KR101738063B1 (ko) 2012-09-21 2017-05-19 아로그 파마슈티칼스, 인코퍼레이티드 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型ｃ－ｋｉｔ的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678604A (zh) * 2002-08-28 2005-10-05 辉瑞产品公司 可用作抗增殖剂的新苯并咪唑衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHAEL C. HEINRICH等人: "Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors", 《CLINICAL CANCER RESEARCH》 *
NANCY L. LEWIS等人: "Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers", 《JOURNAL OF CLINICAL ONCOLOGY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014519A1 (zh) * 2016-07-18 2018-01-25 北京雅康博生物科技有限公司 用于检测c-kit基因突变的引物、探针及试剂盒
CN107382983A (zh) * 2017-08-24 2017-11-24 扬州市三药制药有限公司 一种治疗白血病药物的合成方法
CN107382983B (zh) * 2017-08-24 2020-08-07 扬州市三药制药有限公司 一种治疗白血病药物的合成方法

Also Published As

Publication number Publication date
US20180125839A1 (en) 2018-05-10
US20160367545A1 (en) 2016-12-22
KR20170119659A (ko) 2017-10-27
US9889127B2 (en) 2018-02-13
US20140088147A1 (en) 2014-03-27
AU2013204841B2 (en) 2016-04-28
MX368707B (es) 2019-10-11
CN109010340A (zh) 2018-12-18
TW201417815A (zh) 2014-05-16
MX2013010840A (es) 2015-04-27
JP6042157B2 (ja) 2016-12-14
CA2812258C (en) 2016-12-13
KR101886006B1 (ko) 2018-08-06
US9480683B2 (en) 2016-11-01
JP2014065696A (ja) 2014-04-17
KR20140040594A (ko) 2014-04-03
US10251877B2 (en) 2019-04-09
CA2812258A1 (en) 2014-03-26
TWI599356B (zh) 2017-09-21
AU2013204841A1 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
TWI599356B (zh) 抑制突變型ｃ－ｋｉｔ的方法
EP2491032B1 (en) Akt inhibitors
CA2752114C (en) Fused pyrimidines as akt inhibitors
TW200804386A (en) Imidazopyrazines as protein kinase inhibitors
CN108883112A (zh) 用于癌症患者分级和癌症治疗的化合物、组合物和方法
US10835525B2 (en) Method of inhibiting mutant C-KIT
JP2025512710A (ja) Ｃｄｋ２阻害剤の固体形態、塩、ならびに調製プロセス
KR20250067120A (ko) 의학적 치료를 위한 시클린-의존성 키나제 2 억제제
CA3231240A1 (en) Ink4 tumor suppressor proteins mediate resistance to cdk4/6 kinase inhibitors
US20230241052A1 (en) Method of inhibiting mutant c-kit
EP2651949B1 (en) Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
CN113166140A (zh) Cdk8/19抑制剂
US20180164317A1 (en) Method for stratification of melanoma patients by determination of oxygen consumption, ppargc1a, ppargc1b and mitf levels
JP2022545387A (ja) がんの処置方法
WO2016166159A1 (en) Medical uses and methods for treating cancer using monopolar spindle 1 (mps1) kinase inhibitors
Giarolla et al. Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception
RU2822479C2 (ru) Соединения имидазолонилхинолина и их терапевтическое применение
HK40058347A (en) Cdk8/19 inhibitors
HK40030306A (en) Polymorphic form of tg02
HK1166984B (en) Fused pyrimidines as akt inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Texas in the United States

Applicant after: AROG PHARMACEUTICALS LLC

Address before: American Texas

Applicant before: AROG PHARMACEUTICALS LLC

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140326